Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia
- PMID: 15090801
- DOI: 10.1097/00002030-200402200-00015
Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia
Abstract
Objective: To investigate the effect of highly active antiretroviral therapy (HAART) on Kaposi sarcoma-associated herpesvirus (KSHV) DNA load, anti-KSHV antibody responses and KSHV-specific CD8 T cell responses in HIV-infected individuals over a 2 year period.
Design: Prospective study of 27 HIV-infected antiretroviral therapy-naive individuals, with (n = 4) and without KS (n = 23), before HAART and at 3-month intervals, during treatment with HAART.
Methods: Sequential blood samples were collected for anti-KSHV antibody detection, KSHV DNA load in peripheral blood mononuclear cells (PBMC) and plasma, HIV Gag-specific and KSHV-specific CD8 T cell responses, HIV-1 plasma RNA load and CD4 and CD8 T cell counts.
Results: KSHV DNA in PBMC and plasma became less detectable over time during HAART, in particular after 12 months. KSHV DNA was undetectable in plasma after 24 months on HAART. Anti-KSHV lytic, but not latent, antibody levels increased within 12 months of treatment. KSHV-specific CD8 T cell responses were absent prior to HAART but became detectable in some patients within 6 months of starting treatment, and continued to increase thereafter.
Conclusions: HAART (both protease inhibitor-based and non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations) is associated with immune reconstitution to KSHV and with undetectable KSHV viraemia. However, this restoration is apparent (in particular) only after a relatively long (> 24 months) period of treatment. These immune responses could contribute to the decreased incidence of KS during HAART, but it is unlikely to be a complete explanation for the often rapid resolution of KS when HAART is started.
Similar articles
-
Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study.AIDS. 2010 Sep 10;24(14):2245-52. doi: 10.1097/QAD.0b013e32833b7830. AIDS. 2010. PMID: 20543658
-
Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.AIDS. 2007 Jun 19;21(10):1245-52. doi: 10.1097/QAD.0b013e328182df03. AIDS. 2007. PMID: 17545700 Clinical Trial.
-
Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy.J Virol. 2002 Mar;76(6):2634-40. doi: 10.1128/jvi.76.6.2634-2640.2002. J Virol. 2002. PMID: 11861829 Free PMC article.
-
Kaposi' s sarcoma in HIV-positive patients: the state of art in the HAART-era.Eur Rev Med Pharmacol Sci. 2013 Sep;17(17):2354-65. Eur Rev Med Pharmacol Sci. 2013. PMID: 24065230 Review.
-
Targeted therapy for Kaposi sarcoma.BioDrugs. 2009;23(2):69-75. doi: 10.2165/00063030-200923020-00001. BioDrugs. 2009. PMID: 19489649 Free PMC article. Review.
Cited by
-
Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia.Clin Infect Dis. 2016 Nov 1;63(9):1245-1253. doi: 10.1093/cid/ciw519. Epub 2016 Aug 30. Clin Infect Dis. 2016. PMID: 27578823 Free PMC article.
-
Kaposi's sarcoma and its associated herpesvirus.Nat Rev Cancer. 2010 Oct;10(10):707-19. doi: 10.1038/nrc2888. Nat Rev Cancer. 2010. PMID: 20865011 Free PMC article. Review.
-
Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus.Cell Host Microbe. 2008 Nov 13;4(5):470-83. doi: 10.1016/j.chom.2008.09.012. Cell Host Microbe. 2008. PMID: 18996347 Free PMC article.
-
The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency.Future Microbiol. 2011 Dec;6(12):1399-413. doi: 10.2217/fmb.11.137. Future Microbiol. 2011. PMID: 22122438 Free PMC article. Review.
-
Professional antigen presenting cells in human herpesvirus 8 infection.Front Immunol. 2013 Jan 21;3:427. doi: 10.3389/fimmu.2012.00427. eCollection 2012. Front Immunol. 2013. PMID: 23346088 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials